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In this study was evaluated the chronic cardiac eﬀects of a formulation developed by including angiotensin(Ang)-(1–7) in
hydroxypropyl β-cyclodextrin (HPβCD), in infarcted rats. Myocardial infarction (MI) was induced by left coronary artery
occlusion. HPβCD/Ang-(1–7) was administered for 60 days (76μg/Kg/once a day/gavage) starting immediately before infarction.
Echocardiography was utilized to evaluate usual cardiac parameters, and radial strain method was used to analyze the velocity and
displacement of myocardial ﬁbers at initial time and 15, 30, and 50 days after surgery. Real-time PCR was utilized to evaluate the
ﬁbrotic signaling involved in the remodeling process. Once-a-day oral HPβCD/Ang-(1–7) administration improved the cardiac
function and reduced the deleterious eﬀects induced by MI on TGF-β and collagen type I expression, as well as on the velocity and
displacement of myocardial ﬁbers. These ﬁndings conﬁrm cardioprotective eﬀects of Ang-(1–7) and indicate HPβCD/Ang-(1–7)
as a feasible formulation for long-term oral administration of this heptapeptide.
1.Introduction
Cardiovascular diseases remain the leading cause of morbid-
ity and mortality worldwide mainly due to their ischemic
conditions [1]. Moreover, coronary artery disease is the most
common reason of heart failure in Westernized nations [2].
Thus, the continuous search for therapies that are eﬀective in
reducingtheincidenceofthesepathologiesisstillimperative.
Sinceitsdiscoveryin1988[3],thebiologicallyactivehep-
tapeptide angiotensin(Ang)-(1–7) has been widely studied.
This is mainly due to the observation that its eﬀects are often
opposite to those attributed to Ang II, whose actions favor
the development of pathologic conditions in the heart [2, 4]
and in other organs [5, 6] by binding to the AT1 receptor.
In fact, several studies have demonstrated that Ang-(1–7)
exertsbeneﬁcialeﬀectsinvariousorgans[7,8],including the
heart. In this organ, it promotes antiarrhythmogenic eﬀects
[9], potentiation of the bradykinin vasodilatory eﬀect [10],
improvement of the cardiac function [11–15], reduction of
the release of norepinephrine [16], and regulation of the cell
growth and cardiac remodeling [4, 17–20]. Many of these
eﬀects are mediated by the activation of the Mas receptor
[4, 9, 10, 14, 18] which was identiﬁed as an endogenous
binding site for Ang-(1–7) [21].
In the heart, an increased activity of the classical
axis of the renin-angiotensin system (RAS) composed by
angiotensin-converting enzyme (ACE), Ang II, and AT1
receptor leads to ventricular hypertrophy, heart failure2 International Journal of Hypertension
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Figure 1: Eﬀects of HPβCD/Ang-(1–7) on echocardiographic parameters after left coronary artery ligation in rats followed for up to 50
days. (a) Fractional shortening, (b) ejection fraction, (c) end systolic left ventricular volume, (d) end diastolic left ventricular volume, (e)
interventricular septal dimension in systole, and (f) interventricular septal dimension in diastole.
∗P<0.05 versus sham;
∗∗P<0.01 versus
sham;
∗∗∗P<0.001 versus sham;
†P<0.05 versus MI (two-way ANOVA followed by the Bonferroni posttest).International Journal of Hypertension 3
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Figure 2: Representative M-mode images showing cardiac function and left ventricle chamber dimensions in sham, MI, and MI +
HPβCD/Ang-(1–7)-treated rats. Note the marked increase in end-systolic dimension (ESD) and in end-diastolic dimension (EDD) after
infarction and the improvement in the cardiac function after 50 days in rats treated with HPβCD/Ang-(1–7).
[22, 23], and ﬁbrosis [4, 19]. The excessive ﬁbrosis caused
by maladaptive remodeling processes contributes to the dias-
tolic and systolic dysfunction by increasing the myocardial
stiﬀness and by reducing the pumping capacity [24]. The
locally produced cytokine transforming growth factor β
(TGF-β) is a major mediator of this process [25]. Its expres-
sion is increased in many cardiac pathologies such as hyper-
trophic and dilated cardiomyopathy [26–28] and myocardial
infarction [29, 30]. In this latter condition, evidences suggest
thatTGF-βhasacentralroleintheinﬂammatoryandﬁbrotic
phase of the healing process and may critically modulate
many cellular steps of the postinfarction repair process by
mediating cardiomyocyte growth, ﬁbroblast activation, and
extracellular matrix deposition [30]. Furthermore, TGF-β is
considered an important marker for the transition course of
stable hypertrophy to heart failure [31].
Recently, we have demonstrated that the inclusion
of Ang-(1–7) into the oligosaccharide hydroxypropyl β-
cyclodextrin (HPβCD) [32]i sa ne ﬀective formulation for
oral administration of this heptapeptide [12]. Here, we
aimed to evaluate the eﬀects of long-term administration
of the HPβCD/Ang-(1–7) inclusion compound on cardiac
dysfunction and ﬁbrosis caused by myocardial infarction
(MI) in rats. Additionally, the expression levels of collagen
type I and TGF-β were also analyzed in the hearts.
2. Methods
2.1. Animals. Male Wistar rats weighing 180 to 210g
(approximately 3 months of age) were used in this study.
The animals were provided by the animal facilities of the
Biological Sciences Institute (CEBIO, Federal University of
Minas Gerais) and housed in a temperature- and humidity-
controlled room maintained on a 12:12-h light-dark sched-
ule with free access to food and water. All animal procedures
were performed in accordance with institutional guidelines
approved by local authorities.
2.2. Experimental Groups. The animals were divided into
three groups: sham surgery treated with HPβCD (n =
8), vehicle-treated MI (infarction plus HPβCD, n = 7),
a n dM I+H P βCD/Ang-(1–7) [infarction plus HPβCD/Ang-
(1–7), n = 7]. The treatment with vehicle (HPβCD;
46μg/kg/day in distilled water by gavage) or HPβCD/Ang-
(1–7) (76μg/kg/day in distilled water by gavage) started
in the ﬁrst day of MI, and the rats were killed, and the
hearts were harvested for real-time PCR analysis 60 days
after the beginning of the treatment. The ﬁnal volume of
gavage[HPβCDandHPβCD/Ang-(1–7)] wasapproximately
0.5mL.Thirty-oneanimalsinitiated theexperimentalproto-
cols.Threeratsdiedwithin48hoursaftertheMIsurgeryand
one sham-operated animal died afterone week. Additionally,
ﬁve animals were excluded due to abnormal increases in the
right atria detected by the echocardiographic exam at the
initial examination or due to marked weight loss during the
period of treatment.
2.3. Myocardial Infarction. MI was induced by proximal left
anterior descending (LAD) coronary artery occlusion and
performedunderanesthesiawith10%ketamine/2%xylazine
(4:3, 0.1mL/100g, i.p.). The animals were placed in supine
position on a surgical table, tracheotomized, intubated,
and ventilated with room air using a respirator for small
rodents. The chest was opened by a left thoracotomy at
the third or fourth intercostal space. After the incision of
the pericardium, the heart was quickly removed from the
thoracic cavity and moved to the left to allow access to the
proximal LAD coronary artery. A 4-0 silk suture was snared
around the LAD and carefully ligated to occlude the vessel.
Theheartwasthenplacedback,andthechestwasclosedwith4 International Journal of Hypertension
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Figure 3: Eﬀects of HPβCD/Ang-(1–7) on the variation of the velocity and displacement in rats after (a and b) 15 days; (c and d) 30 days,
and (e and f) 50 days of treatment.
∗P<0.05 versus sham;
†P<0.05 versus MI;
‡P<0.01 versus MI (one-way ANOVA followed by the
Newman-Keuls posttest).
4-0 silk sutures. Sham-operated rats were treated in the same
manner, but the coronary artery was not ligated.
2.4. Echocardiography Analysis. Animals underwent trans-
thoracic echocardiographic examination before the surgery
andafter15,30,and50daysofLADcoronaryarteryligation.
In vivo cardiac morphology and function were assessed non-
invasively using a high-frequency, high-resolution echocar-
diographic system consisting of a VEVO 2100 ultrasound
machine equipped with a 16–21MHz bifrequencial trans-
ducer(Visual Sonics, Toronto, Canada). The rats were anaes-
thetized with 3.5% isoﬂurane for induction, the anterior
chest was shaved, and the rats were placed in supine position
on an imaging stage equipped with built-in electrocardio-
graphic electrodes for continuous heart rate monitoring andInternational Journal of Hypertension 5
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Figure 4: Representative images of the radial strain analysis of the velocity (cm/s) at basal conditions and after 15 and 50 days of MI. (a)
sham group, (b) MI group, and (c) MI + HPβCD/Ang-(1–7).
a heater to maintain the body temperature at 37◦C. Anes-
thesia was sustained via a nose cone with 2.5% isoﬂurane.
High-resolution images were obtained in the right and left
parasternal long and short axes and apical orientations.
Standard B-mode images of the heart and pulsed Doppler
images of the mitral and tricuspid inﬂow were acquired.
Left ventricular (LV) dimensions and wall thickness were
measuredatthelevelofthepapillarymusclesinleftandright
parasternalshortaxisduringtheendsystoleandenddiastole.
LV ejection fraction (EF), fractional shortening (FS), and
mass were measured. All the measurements and calculations
were done in accordance with the American Society of
Echocardiography. The following M-mode measurements
were performed: LV internal dimensions at diastole and sys-
tole(LVIDDandLVIDS,resp.),LVposteriorwalldimensions
at diastole and systole (LVPWD and LVPWS, resp.), and
interventricular septal dimensions at diastole and systole
(IVSDD and IVSDS, resp.). Based on these parameters,
end diastolic and end systolic LV volumes (EDLVV and
ESLVV, resp.), FS, EF, stroke volume (SV), and cardiac
output (CO) were calculated. Also, the radial strain from
the bidimensional long axis view of the left ventricle was
performed using the Vevostrain software. The following
parameters were evaluated: velocity, displacement, strain,
and strain rate.
2.5. Plasma Ang-(1–7) Levels Measurement. Blood samples
were collected in tubes through a polypropylene fun-
nel after the decapitation of the animals. These tubes6 International Journal of Hypertension
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Figure 5: Representative images of radial strain analysis of the displacement (mm) at basal conditions and after 15 and 50 days of MI. (a)
sham group, (b) MI group, and (c) MI + HPβCD/Ang-(1–7).
contained 1mmol/L p-hydroxymercuribenzoate, 30mmol/L
1,10-phenanthroline, 1mmol/L PMSF, 1mmol/L pepstatin
A, and 7.5% EDTA (50μL/mL of blood). After centrifuga-
tion, plasma samples were frozen in dry ice and stored at
−80◦C. Peptides were extracted onto a BondElut phenylsi-
lane cartridge (Varian). The columns were preactivated by
sequential washes with 10mL of 99.9% acetonitrile/0.1%
heptaﬂuorobutyric acid (HFBA), and 10mL of 0.1% HFBA.
After sample application, the columns were washed with
20mL of 0.1% HFBA and 3mL of 20% acetonitrile/0.1%
HFBA. The adsorbed peptides were eluted with 3mL of
99.9% acetonitrile/0.1% HFBA into polypropylene tubes
rinsed with 0.1% fat-free BSA. After evaporation, the Ang-
(1–7) levels were measured by radioimmunoassay (RIA), as
previously described [33].
2.6. Reverse Transcription and Real-Time PCR. To perform
the real-time PCR analysis, the hearts were cut transversally
approximately 1mm below the suture point and 3mm above
the apex; thereby, they were divided in 3 parts: basal, middle,
and apical. Only the middle portion, where the majority of
the infarcted tissue was localized, was used for real-time PCR
analysis. Total mRNA isolation was performed following the
TRIzol reagent protocol (Invitrogen Life Technologies). Sev-
en hundred nanograms of mRNA treated with DNAse wereInternational Journal of Hypertension 7
used as template for M-MLV reverse transcriptase (ArrayS-
cript, Ambion) using the following antisense primers: Mas
(3 -GGTGGAGAAAAGCAAGGAGA-5 ), TGF-β (3 -GGTT
CATGTCATGGATGGTGC-5 ), collagen I (3 -CCTTAGGCC
ATTGTGTATGC-5 ), and S26 (3 -CGTGCTTCCCAAGCTC
TATGT-5 ).Real-timePCRwascarriedoutimmediatelyafter
the synthesis of the ﬁrst strand cDNA. The sense primers
used were Mas (5 -ACTGTCGGGCGGTCATCATC-3 ),
TGF-β (5 -TGACGTCACTGGAGTTGTACGG-3 ), collagen
I(5  -TGTTCAGCTTTGTGGACCTC-3 ),andS26(5 -CGAT
TCCTGACAACCTTGCTATG-3 ) and their respective anti-
sense primers as mentioned above. The PCR reactions
containing 300μM of each primer (sense and antisense),
50–100ng of cDNA, and SYBR Green PCR Master Mix
(Applied Biosystems) were run under standard conditions
in an ABI Prism 7000 Sequence Detector. The threshold
cycle (CT) was determined for each sample, and the CT
values of the S26 were subtracted from the CT values of
the experimental samples to obtain ΔCT values. Transcript
levels in left ventricles were expressed as fold relative to the
S26 values (2-ΔΔCT).
2.7. Statistical Analysis. All data are expressed as means ±
SEM. Echocardiographic data were estimated using two-way
ANOVA followed by the Bonferroni posttest. The real-time
PCR data, variation of velocity, and displacement of each
time in relation to the initial time were analyzed using one-
way ANOVA followed by the Newman-Keuls posttest. The
level of signiﬁcance was set at P<0.05 (GraphPad Prism
4.0).
3. Results
3.1. Plasma Ang-(1–7) Levels. Plasma levels of Ang-(1–7)
in blood samples collected 24 hours after the last dose
of HPβCD/Ang-(1–7) in MI rats were higher than those
observed in vehicle-treated rats; however, the diﬀerence
did not reach signiﬁcant statistical diﬀerence (80.16 ±
18.4pg/mL versus 49.7 ± 13.6pg/mL). Plasma levels of
Ang-(1–7) in vehicle-treated sham rats averaged 63 ±
11.7pg/mL.
3.2. Eﬀects of HPβCD/Ang-(1–7) Long-Term Administration
on Echocardiographic Parameters. The echocardiographic
analysis at the initial time (before the surgery) showed
that SV, HR, CO, EF, FS, EDLVV and ESLVV, LV mass,
IVSDD, and IVSDS were similar in all three groups evaluated
(data not shown). The success of the MI procedure was
conﬁrmed by the presence of one of the following changes
in the myocardial kinetics observed during the echocar-
diographic analysis: (i) hypokinesia caused by reduction in
the thickness or wall motion, (ii) akinesia represented by
absence of thickening and/or movement, and (iii) dyskinesia
characterized by changes in the movement in one or more
segments or regions of the heart. Although the body weight
gain was less pronounced in MI vehicle-treated animals,
no signiﬁcant diﬀerenceswere detected among the groups
during the treatment period (Table 1). Also, no signiﬁcant
changes were observed in the LV mass, SV, HR, and CO
during the treatment period. However, the administration of
the inclusion compound to infarcted animals allowed them
to better recover the SV and CO over time (Table 1). As
expected, MI caused a progressive impairment of the cardiac
function evidenced by decreases in the FS (Figure 1(a)), EF
(Figure 1(b)), IVSDS (Figure 1(e)), and IVSDD (Figure 1(f))
and increases in the ESLVV (Figure 1(c)) and EDLVV
(Figure 1(d)). The administration of HPβCD/Ang-(1–7)
signiﬁcantly improved the FS, EF, IVSDS, and ESLVV of
MI animals (Figure 1). Speciﬁcally, after 15 days of surgical
procedure, MI induced a signiﬁcant reduction in the FS
(50%), EF (42%), IVSDS (44%), and a signiﬁcant increase
in the EDLVV (40%) and ESLVV (189%) (Figure 1). The
HPβCD/Ang-(1–7) treatment ameliorated the decrease of
FS,EF,andESLVV;thatis,FSincreased32%(29 ± 2%versus
22 ± 1%invehicle-treatedMIrats),EFincreased26%(54 ±
3% versus 43 ± 2% in vehicle-treated MI rats), and ESLVV
decreased 20% (152 ± 19μL versus 191 ± 10μL in vehicle-
treated MI rats). Thirty days after MI induction, control
infarcted animals showed a similar proﬁle as observed at the
15 days of MI. An increase of 52% and 214% in the EDLVV
and ESLVV was observed, respectively. Furthermore, an
additional reduction in the IVSDS of untreated MI rats was
observed (36%). Again, the treatment with HPβCD/Ang-
(1–7) induced an improvement in all parameters analyzed,
including a signiﬁcant attenuation of the reduction in the
IVSDD (1.2 ± 0.11mm versus 0.9 ± 0.13mm in vehicle-
treated MI rats). At the end of the 50 days postinfarction
period, no further alterations in the cardiac function of the
vehicle-treated infarcted rats were observed; in contrast, the
HPβCD/Ang-(1–7)-treated rats showed an improvement of
all cardiac parameters evaluated, that is, FS (26 ± 2% versus
19 ± 1% in vehicle-treated MI rats), EF (49 ± 3% versus
37 ± 2%invehicle-treatedMIrats),IVSDS(2.0 ± 0.21mm
versus 1.5 ± 0.08mm in vehicle-treated MI rats), IVSDD
(1.3 ± 0.1mm versus 1.1 ± 0.06mm in vehicle-treated
MI rats), EDLVV (364 ± 27μL versus 445 ± 27μLi n
vehicle-treated MI rats), and ESLVV (189 ± 23μLv e r s u s
282 ± 25μL in vehicle-treated MI rats) (Figures 1 and 2).
3.3. Eﬀects of Long-Term Administration of HPβCD/Ang-
(1–7) on Radial Strain Parameters. Radial strain analysis
of the bidimensional long axis view of the LV revealed
that MI induced a signiﬁcant decrease in the velocity and
displacement of myocardial ﬁbers at 15, 30, and 50 days after
surgery. HPβCD/Ang-(1–7) treatment completely reversed
thereductionobservedinthedisplacementofthemyocardial
ﬁbers at all periods of evaluation after infarction (15, 30, and
50 days after surgery—Figures 3(b), 3(d), and 3(f), resp.)
as well as in the velocity of myocardial ﬁbers at 50 days
after MI induction (Figure 3(e)). In addition, the velocity
of myocardial ﬁbers was improved in infarcted rats treated
withHPβCD/Ang-(1–7)after15and30daysofMIinduction
(Figures3(a)and3(b),resp.).Three-dimensionalrepresenta-
tivediagramsofvelocityanddisplacementobtainedbyradial
strain are shown in Figures 4 and 5,r e s p e c t i v e l y .8 International Journal of Hypertension
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Figure 6: Eﬀects of long-term administration of HPβCD/Ang-(1–7) on mRNA expression of (a) TGF-β, (b) collagen type I, and (c) Mas in
infarcted animals.
∗P<0.05 and
∗∗P<0.01 versus sham;
†P<0.01 versus MI (one-way ANOVA followed by the Newman-Keuls posttest)
(a.u) = Arbitrary Units.
3.4. Eﬀects of HPβCD/Ang-(1–7) Long-Term Administration
on Mas, TGF-β,a n dC o l l a g e nT y p eIm R N AE x p r e s s i o n .
At the end of the treatment, real-time PCR assays were
performed in order to evaluate the Mas, TGF-β,a n dc o l l a g e n
type I gene expression. We found that vehicle-treated
infarcted animals presented an increased expression of TGF-
β (Figure 6(a))a n dc o l l a g e nt y p eI( Figure 6(b)) in the heart
ascomparedwithsham-operated rats.The administration of
HPβCD/Ang-(1–7) in MI animals abolished the increase of
collagentypeImRNAexpressionandreducedtheincreasein
the expression of TGF-β mRNA. Although the expression of
Mas tended to increase in MI rats, it did not reach statistical
signiﬁcance when compared with sham-operated animals
(Figure 6(c)).
4. Discussion
In the present study, we demonstrated that once-a-day
chronic oral administration of the inclusion compound
HPβCD/Ang-(1–7) produced progressive time-dependent
cardioprotective eﬀects in MI animals. Speciﬁcally, we
found that chronic oral administration of HPβCD/Ang-(1–
7) improves the diastolic and systolic function and reduces
the expression of ﬁbrosis scar markers (TGF-β and collagen
type I).
MI is a common cause of heart failure in humans [2, 34,
35],andtheratmodelofMIproducedbycoronaryarterylig-
ation has been used extensively to study the pathophysiology
of this condition as well as new approaches to its treatment
[12,35,36].Inkeepingwithapreviousstudy[37],ourresults
indicate that the progressive increase in diastolic LV volume
was the main mechanism underlying the maintenance of
the stroke volume in the presence of a prominent decrease
in the FS. Importantly, the treatment with HPβCD/Ang-(1–
7) caused a signiﬁcant time-dependent improvement in LV
dilation demonstrated by the attenuation of the changes in
ESLVV and EDLVV.
It has been recently proposed that measurement of the
myocardial deformation (velocity, displacement, strain, and10 International Journal of Hypertension
strainrate)isapowerfultechniquetomeasureheartfunction
disturbances [38, 39]. In this study, we used this approach to
evaluate functional changes induced by MI and the eﬀects
of HPβCD/Ang-(1–7) on these alterations. A signiﬁcant
improvement in the velocity and displacement of the cardiac
ﬁbersinanimalstreatedwiththisheptapeptidewasobserved.
The increased deposition of collagen in the heart and
abnormal extracellular matrix structure result in myocardial
stiﬀness,leadingtoventricularsystolicanddiastolicdysfunc-
tion [24, 35, 37]. Our data are in keeping with these concepts
since we observed that chronic treatment with HPβCD/Ang-
(1–7) attenuated these alterations, evidenced by a smaller fall
in EF and FS and by a smaller reduction in the thickness
of the cardiac ﬁbers in both systole (IVSDS) and diastole
(IVSDD), which was accompanied by a decrease expression
of TGF-β and collagen type I.
Cardiac ﬁbroblasts are the primary source of TGF-
β in the heart [30], and it was demonstrated that this
cytokine is absolutely required for the Ang II-induced
cardiac hypertrophy in vivo [30], and regulates the collagen
synthesis in cardiac ﬁbroblasts [40, 41]. Thus, there are
evidences supporting a direct functional association between
the RAS and TGF-β pathways [42]. It has been suggested
that Smad proteins are the main downstream mediators
of the cardiac Ang II/TGF-β1 pathway in the chronic
phase of MI [28]. Furthermore, it was observed that TGF-
β1/TAK1/p38MAPK-signaling pathway is activated in spared
cardiomyocytes following MI and can play an important
role in the development of hypertrophy in the remodeling
myocardium [43]. On the other hand, it is well documented
that Ang-(1–7) acting through the Mas receptor counter
regulates the Ang II eﬀects [4, 9, 10, 14, 18, 19, 44, 45].
Although our results did not show statistical diﬀerences in
the expression of Mas among any of the groups, they clearly
demonstrated that the administration of HPβCD/Ang-(1–7)
in infarcted animals induced a reduction in the increase of
TGF-β mRNAexpression.Theseﬁndingscanexplain,atleast
partially, the beneﬁcial eﬀects of the inclusion compound
in MI. Moreover, the improvement in the heart function of
MI rats by HPβCD/Ang-(1–7) treatment could be related
to the reduction of the infarcted area as demonstrated in
our previous study [12] which is in keeping with the strain
analysis showing an improvement of the ventricular wall
displacement in the HPβCD/Ang-(1–7)-treated MI rats.
One special feature of the Ang-(1–7) is its long-term
eﬀectiveness, as demonstrated in this study. Indeed, this
observation is in keeping with previous studies showing
beneﬁcial eﬀects of chronic Ang-(1–7) administration in
diﬀerent models of cardiovascular diseases [4, 11, 13, 14,
20, 44, 46]. Chronic Ang-(1–7) administration improved LV
function of Wistar rats [47] and of diabetic spontaneously
hypertensive rats (SHRs) [14] after global ischemia, atten-
uated the heart failure induced by MI [11], prevented the
development of severe hypertension and end-organ damage
in SHR treated with L-NAME [13], and reduced the cardiac
remodeling in DOCA-salt and in Ang II-infused rats [4, 20].
In addition, an antiﬁbrotic eﬀect was observed in transgenic
animals, which chronically present an increased plasma Ang-
(1–7) levels [46].
In summary, this study showed that long-term treatment
with HPβCD/Ang-(1–7) was able to attenuate the maladap-
tive remodeling events caused by MI, thereby indicating that
Ang-(1–7) holds beneﬁcial eﬀects in hearts and that this
inclusioncompoundconstitutesaneﬀectivestrategytoorally
administer this heptapeptide.
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